Advertisement
UK markets closed
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     
  • AIM

    745.67
    +0.38 (+0.05%)
     
  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     
  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     
  • Bitcoin GBP

    52,056.12
    +762.11 (+1.49%)
     
  • CMC Crypto 200

    1,386.96
    +74.34 (+5.66%)
     
  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     
  • DOW

    37,986.40
    +211.02 (+0.56%)
     
  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     
  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     

Alexion Earnings, Revenue Beat in Q4

Alexion Earnings, Revenue Beat in Q4
Alexion Earnings, Revenue Beat in Q4

Investing.com - Alexion reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.

Alexion announced earnings per share of $2.71 on revenue of $1.38B. Analysts polled by Investing.com anticipated EPS of $2.59 on revenue of $1.31B. That with comparison to EPS of $2.14 on revenue of $1.13B in the same period a year before. Alexion had reported EPS of $2.79 on revenue of $1.26B in the previous quarter. Analysts are expecting EPS of $2.71 and revenue of $1.34B in the upcoming quarter.

Alexion shares are down 1.12% from the beginning of the year and are trading at $106.94 , still down 24.62% from its 52 week high of $141.86 set on April 10, 2019. They are under-performing the S&P 500 which is up 0.87% year to date.

Alexion follows other major Healthcare sector earnings this month

Alexion's report follows an earnings beat by J&J on January 22, who reported EPS of $1.88 on revenue of $20.75B, compared to forecasts EPS of $1.87 on revenue of $20.8B.

ADVERTISEMENT

Novartis ADR had beat expectations on Wednesday with fourth quarter EPS of $1.32 on revenue of $12.4B, compared to forecast for EPS of $1.31 on revenue of $12.33B.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Related Articles

Coca-Cola Earnings inline, Revenue Beats In Q4

Biogen Earnings, Revenue Beat in Q4

Mike Ashley's Frasers cleared over bulk of Belgian tax case